Alembic Pharma iron tablet Deferasirox gets USFDA nod
Deferasirox tablets are indicated for the treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) and for treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes.
Vadodara: Alembic Pharmaceuticals Limited today announced that the Company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Deferasirox Tablets, 180 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jadenu Tablets, 180 mg, of Novartis Pharmaceuticals Corporation (Novartis).
Deferasirox tablets are indicated for the treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) and for treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes.
Alembic had previously received final approval for Deferasirox Tablets, 90 mg and 360 mg and tentative approval for Deferasirox Tablets, for 180 mg.
Deferasirox Tablets, 180 mg have an estimated market size of US$ 53 million for twelve months ending March 2020 according to IQVIA.
Alembic now has a total of 122 ANDA approvals (109 final approvals and 13 tentative approvals) from USFDA.
Read also: Alembic Pharma gets USFDA Final nod for Doxycycline Hyclate Tablets
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.
Read also:Alembic Pharma JV gets USFDA nod for Clobetasol Propionate Shampoo
